SB 373 – New Mexico

Status: Inactive / Dead
Year Introduced: 2019

DRUG PRICE TRANSPARENCY ACT: By March 1 of each year, each manufacturer of brand-name or generic drugs sold in the state shall report to the department the value of price concessions provided to each pharmacy benefits manager for each drug sold to providers or residents in the state in the previous calendar year, expressed as a percentage of the wholesale acquisition cost.

Return to Database Search

© 2018- The SLIHCQ DatabaseInitial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.

Associated Litigation:

No items found